Axsome Therapeutics, Inc. AXSM NASDAQ

Axsome Therapeutics, Inc. (AXSM) generated $-93.41M in operating cash flow for fiscal year 2025. After capital expenditures of $480K, free cash flow was $-93.89M.

Free cash flow margin was -14.7% of revenue. Cash conversion ratio was 0.51x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (33/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (70/100, Pass) — $-93.89M (-14.7% FCF margin) supports a durable competitive advantage
• INCOME (10/100) — Cash conversion ratio was 0.51x suggests some earnings are non-cash items

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.